Israel Englander Ultragenyx Pharmaceutical Inc. Transaction History

Millennium Management LLC

$175 Billion
Q1 2025

A detailed history of Israel Englander (Millennium Management LLC) transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Millennium Management LLC holds 712,393 shares of RARE stock, worth $26.6 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

712,393

Previous 697,236 2.17%

Holding current value

$26.6 Million

Previous $29.3 Million 12.06%

% of portfolio

0.01%

Previous 0.02%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$36.21 - $45.78 $548,834 - $693,887	15,157 Added 2.17%	712,393 $25.8 Million
Q4 2024 Feb 14, 2025	SELL	$42.07 - $57.72 $565,967 - $776,507	-13,453 Reduced 1.89%	697,236 $29.3 Million
Q3 2024 Nov 14, 2024	SELL	$40.21 - $59.36 $45.8 Million - $67.7 Million	-1,140,045 Reduced 61.6%	710,689 $39.5 Million
Q2 2024 Aug 14, 2024	BUY	$37.42 - $51.61 $42.8 Million - $59 Million	1,142,829 Added 161.44%	1,850,734 $76.1 Million
Q1 2024 May 15, 2024	BUY	$43.02 - $53.69 $29.2 Million - $36.5 Million	679,353 Added 2379.35%	707,905 $33.1 Million
Q4 2023 Feb 14, 2024	SELL	$31.73 - $49.19 $853,314 - $1.32 Million	-26,893 Reduced 48.5%	28,552 $1.37 Million
Q2 2023 Aug 14, 2023	SELL	$37.35 - $52.15 $26.4 Million - $36.8 Million	-706,402 Reduced 92.72%	55,445 $2.56 Million
Q1 2023 May 15, 2023	SELL	$36.99 - $48.71 $402,451 - $529,964	-10,880 Reduced 1.41%	761,847 $30.6 Million
Q4 2022 Feb 14, 2023	BUY	$33.72 - $46.33 $16.1 Million - $22.1 Million	477,325 Added 161.58%	772,727 $35.8 Million
Q3 2022 Nov 14, 2022	BUY	$39.96 - $66.14 $6.86 Million - $11.3 Million	171,571 Added 138.55%	295,402 $12.2 Million
Q2 2022 Aug 15, 2022	BUY	$45.8 - $85.4 $5.33 Million - $9.94 Million	116,413 Added 1569.33%	123,831 $7.39 Million
Q1 2022 May 16, 2022	SELL	$62.2 - $84.4 $3.47 Million - $4.71 Million	-55,822 Reduced 88.27%	7,418 $539,000
Q4 2021 Feb 14, 2022	SELL	$73.71 - $87.86 $3.28 Million - $3.91 Million	-44,524 Reduced 41.32%	63,240 $5.32 Million
Q3 2021 Nov 15, 2021	SELL	$77.92 - $102.4 $35.5 Million - $46.7 Million	-455,623 Reduced 80.87%	107,764 $9.72 Million
Q2 2021 Aug 16, 2021	BUY	$92.19 - $115.71 $51.7 Million - $64.9 Million	561,292 Added 26791.98%	563,387 $53.7 Million
Q4 2020 Feb 16, 2021	SELL	$84.4 - $177.39 $325,615 - $684,370	-3,858 Reduced 64.81%	2,095 $290,000
Q3 2020 Nov 16, 2020	SELL	$72.98 - $90.0 $3.62 Million - $4.46 Million	-49,570 Reduced 89.28%	5,953 $489,000
Q2 2020 Aug 14, 2020	BUY	$46.91 - $78.22 $1.98 Million - $3.3 Million	42,129 Added 314.54%	55,523 $4.34 Million
Q1 2020 May 14, 2020	BUY	$33.8 - $62.9 $452,717 - $842,482	13,394 New	13,394 $595,000
Q4 2019 Feb 14, 2020	SELL	$36.08 - $45.83 $209,733 - $266,409	-5,813 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$42.5 - $63.11 $247,052 - $366,858	5,813 New	5,813 $248,000
Q4 2018 Feb 14, 2019	SELL	$38.89 - $77.3 $675,208 - $1.34 Million	-17,362 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$71.81 - $90.15 $1.25 Million - $1.57 Million	17,362 New	17,362 $1.33 Million
Q2 2018 Aug 14, 2018	SELL	$48.54 - $85.31 $14.6 Million - $25.6 Million	-300,260 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$44.33 - $58.52 $7.82 Million - $10.3 Million	176,425 Added 142.47%	300,260 $15.3 Million
Q4 2017 Feb 14, 2018	BUY	$43.54 - $57.32 $1.62 Million - $2.14 Million	37,315 Added 43.13%	123,835 $5.74 Million
Q3 2017 Nov 14, 2017	BUY	$49.79 - $66.32 $4.31 Million - $5.74 Million	86,520	86,520 $4.61 Million

Others Institutions Holding RARE

# of Institutions

336

Shares Held

88.9M

Call Options Held

1.08M

Put Options Held

1.04M

View Full List

About Ultragenyx Pharmaceutical Inc.

Ticker RARE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,036,896
Market Cap $2.62B
Description
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...

More about RARE

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account